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Pemetrexed is a multitarget antifolate agent used to treatrecurrent non-small cell lung cancer (NSCLC) after prior
platinum-based chemotherapy. In a large phase III study,
compared with docetaxel, pemetrexed was shown to have
similar response rates and disease stabilization, with a better
safety profile.1 Pemetrexed has not been considered as a
cause of acute lung injury. However, here, we present a case
of acute lung injury associated with pemetrexed in a patient
with metastatic patient.
CASE REPORT
A 61-year-old woman was admitted to our hospital.
Seven months before admission, she was diagnosed with
NSCLC (adenocarcinoma, pT2N2M0) and treated with a
right lower lobectomy. Adjuvant chemotherapy was started
with vinorelbine and cisplatin, but the chemotherapeutic
regimen was changed to pemetrexed after four cycles due to
pleural metastasis.
Shortly after the fourth cycle of pemetrexed treat-
ment, the patient complained of dyspnea. Chest x-rays and
computer tomography scan (Figure 1B) revealed diffuse
pulmonary infiltration, and the lesion progressed rapidly.
No bacterial pathogen was cultured in induced sputum, and
Acid fast stain was also negative. Serologic data did not
show any evidence of infection, cardiac, or collagen vas-
cular disease as a cause of the acute lung injury. As
dyspnea was so severe, we could not perform the bron-
choscopy and bronchoalveolar lavage for culture. The
patient underwent a video-assisted thoracoscopic lung bi-
opsy. The pathology revealed diffuse alveolar septal thick-
ening with hyaline membranes, and Grocott’s methena-
mine silver stain of the biopsy specimen did not reveal any
evidence of specific infiltration (Figure 2). After pred-
nisolone 60mg/d (oral) was started, the dyspnea and pul-
monary infiltrations slowly improved (Figure 1C).
Comment
Many chemotherapeutic agents have been associ-
ated with pulmonary toxicity. The onset of symptoms is
unpredictable and generally rapidly progressive. Further-
more, chemotherapy-induced lung injury can manifest in
many different patterns and can be severe or fatal. The
diagnosis depends on clinical, radiologic, and histologic
findings.2 However, in the clinical setting, the diagnosis is
made by excluding other conditions with similar manifes-
tations. Early withdrawal of the offending drug and judi-
cious treatment with steroid will often lead to improve-
ment or complete resolution of the chemotherapy-induced
lung injury.3
Many drugs have been associated with lung injury
characterized by diffuse alveolar damage (DAD); this histo-
logic pattern is common in a majority of patients with lung
injury due to chemotherapeutic agents. Histologically, DAD
is diagnosed with the findings of alveolar airspace and inter-
stitial edema, hyaline membrane formation, and proliferation
of type II pneumocytes. Mechanisms of damage include
direct pulmonary toxicity and indirect effects caused by
stimulation of inflammatory reactions.4
Pemetrexed is a newly developed antifolate drug that
targets multiple enzymes involved in DNA synthesis and
folate metabolism. Pemetrexed is currently being used as a
standard agent for second line chemotherapy in patients with
NSCLC due to prolonged survival time and modest side
effects. The most frequent toxicities reported in patients
treated with pemetrexed are fatigue, neutropenia, and infec-
tion.5 Pulmonary toxicity resulting from treatment with pem-
etrexed has not been previously reported with pathologic
confirmation.
There are no established criteria for the diagnosis of
chemotherapy-induced lung injury and the pathologic find-
ings of drug-related DAD. Thus, the diagnosis is possible by
exclusion of other conditions that cause lung injury.2,3 In our
case, the clinical history, histologic evidence of lung injury,
and exclusion of other potential factors suggested the chemo-
therapeutic drug as the cause of the acute lung injury. This is
the first case of pathologically proven lung injury due to
pemetrexed.
In conclusion, this patient demonstrated an acute lung
injury with the histologic pattern of DAD associated with
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pemetrexed treatment. Currently, pemetrexed is used as a
standard agent for second line chemotherapy in patients with
NSCLC. Because pemetrexed may cause acute lung injury in
some patients, careful follow-up of patients treated with
pemetrexed is required.
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FIGURE 1. Summary of chest computer tomography (CT) before presentation of acute lung injury (A), at presentation (B),
and after some improvement (C).
FIGURE 2. The microscopic examination of the lung
specimen revealed diffuse alveolar septal thickening by
fibroblasts and scant chronic inflammatory cells, which
was consistent with the features of an organizing stage of
diffuse alveolar damage. Within the alveolar lumen, some
remnants of hyaline membranes were observed (100,
hematoxylin and eosin [H and E]).
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